Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$27.87−1.17 (-4.03%)
Close on Nov 16, 2026Market cap $4.45BP/E –Yield –
Adaptive Biotechnologies total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Adaptive Biotechnologies's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $131.21M, down 1.6% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.21M | -1.6% |
| FY2024 | Dec 31, 2024 | $133.28M | +2.0% |
| FY2023 | Dec 31, 2023 | $130.66M | +4.2% |
| FY2022 | Dec 31, 2022 | $125.36M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $130.55M | -2.3% |
| Q4 FY2025 | Dec 31, 2025 | $131.21M | -1.6% |
| Q3 FY2025 | Sep 30, 2025 | $131.84M | -0.6% |
| Q2 FY2025 | Jun 30, 2025 | $133.57M | +1.1% |
| Q1 FY2025 | Mar 31, 2025 | $133.56M | +1.5% |
| Q4 FY2024 | Dec 31, 2024 | $133.28M | +2.0% |
| Q3 FY2024 | Sep 30, 2024 | $132.70M | +2.1% |
| Q2 FY2024 | Jun 30, 2024 | $132.08M | +5.4% |
| Q1 FY2024 | Mar 31, 2024 | $131.55M | – |
| Q4 FY2023 | Dec 31, 2023 | $130.66M | – |
| Q3 FY2023 | Sep 30, 2023 | $129.92M | – |
| Q4 FY2022 | Dec 31, 2022 | $125.36M | – |
See a number that looks wrong?